Clinical trials located in

Düsseldorf

Düsseldorf city is located in Germany. Currently, 8 clinical trials are being conducted in this city.

Düsseldorf, the capital city of North Rhine-Westphalia, Germany, stands out for its vibrant arts scene, cutting-edge architecture, and rich history. The city is renowned for its fashion industry and the Königsallee, one of the most luxurious shopping streets in Europe. Düsseldorf also boasts a lively cultural landscape, with the Kunstpalast museum showcasing a wide array of art. The Altstadt, known as the “longest bar in the world,” offers over 260 bars and restaurants. The Rhine Tower provides panoramic views, while the annual Karneval brings the city to life with its colorful parades and festivities.

  • CT-EU-00116246

    Study of TL-895 Combined with Ruxolitinib for Myelofibrosis Treatment

    This here clinical trial is studying a new experimental drug called TL-895 for the treatment of myelofibrosis. TL-895 works by blocking certain proteins called tyrosine kinases that are involved in the growth of cancer cells. The study is open to folks who have myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.

    Participants in the study will take TL-895 along with another drug called ruxolitinib, which is already approved for treating myelofibrosis. Ruxolitinib, also known as Jakafi or Jakavi, works by blocking different proteins called Janus kinases that are also involved in cancer growth.

    The main goal of the study is to find the best dose of TL-895 to use with ruxolitinib that is both safe and effective. In the first part, different doses of TL-895 will be tested to determine the highest dose that can be tolerated without causing too many side effects. Then in the second part, the recommended dose will be given to all participants, and the researchers will measure how well the combination of drugs reduces spleen size after 24 weeks of treatment.

    So in a nutshell, this study aims to test a new targeted therapy for myelofibrosis by combining it with an existing approved drug, with the hope of improving treatment outcomes for patients with this serious blood disorder.

    • TL-895
    • Ruxolitinib
  • Evaluating new medication in congenital hyperinsulinism treatment

    This clinical trial is focused on testing a new treatment called HM15136 for individuals aged 2 years and older who have Congenital Hyperinsulinism (CHI). CHI is a condition that causes persistent low blood sugar levels due to excessive insulin production. The study aims to find out how safe and effective HM15136 is when used alongside standard treatments that participants are already receiving for CHI.

    HM15136 will be given as a subcutaneous (under the skin) injection once a week for 8 weeks. The trial will look into how well the body tolerates this medication, any side effects that might occur, and how the body processes the drug. Additionally, the study will assess the effectiveness of HM15136 in managing blood sugar levels in participants.

    The safety of the participants will be closely monitored throughout the study, focusing on any adverse events, serious adverse events, and changes in clinical laboratory tests. The trial will also measure the highest concentration of the drug in the bloodstream and how long it takes to reach this peak level after administration.

    This study is an opportunity for individuals with CHI to potentially improve their condition and contribute to medical research in finding new treatments for this rare disease.

    • HM15136
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Study of etrasimod in treating intense ulcerative colitis

    This study is a follow-up to previous research for the treatment of people with moderate to serious ulcerative colitis (UC). UC is a condition that inflames the large intestine and causes sores on the inside. The study will monitor the effects and safety of a medicine called etrasimod. This research is for people who have been part of past research trials and wish to continue treatment. Doctors will track a few things like side effects and how the medicine affects the disease in ways they have designed.

    • Etrasimod
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.